BioSpace News Archive

Oryzon Genomics, S.A., a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced that its management will give an update on corporate progress at several international events in February and March.

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and hepatocellular carcinoma (“HCC”), announced today that its CEO, Dr. Robert Foster, will present a corporate overview at the BIO CEO & Investor Conference.

Vaxart, Inc. announced the appointment of Edward B. Berg as the Company’s first in-house General Counsel.

Outlook Therapeutics, Inc. announced recent corporate highlights and financial results for its fiscal first quarter ended December 31, 2021.

Benitec Biopharma Inc., a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference platform, announced the financial results for its Fiscal Year Q2 ended December 31, 2021.

Axcella Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted a Fast Track Designation to AXA1125 for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis.

Aqemia announces it has entered into a pilot study agreement with Janssen.

Primmune Therapeutics presented interim data related to PRTX007, a novel, orally administered, small molecule toll-like receptor 7 (TLR7) specific agonist that is currently in Phase 1 development, at the Conference on Retroviruses and Opportunistic Infections (CROI).

Imperative Care Announces the Launch of Its Zoom POD ™ for Stroke Treatment, the First and Only Filter to Capture Clot in the Sterile Field.

CytRx Corporation today highlighted Orphazyme A/S for the treatment of Niemann-Pick disease type C (“NPC”). CytRx licensed arimoclomol to Orphazyme in exchange for milestone payments and royalties.